Dose escalation of TAS-117 in patients with advanced solid tumors

被引：0

作者：

Rodon, J. ^{[1
]}

Arkenau, H-T. ^{[2
]}

Funchain, P. ^{[3
]}

Hervieu, A. ^{[4
]}

Gao, L. ^{[5
]}

Liu, M. ^{[6
]}

Halim, A. ^{[7
]}

Mina, M. ^{[8
]}

Takahashi, O. ^{[8
]}

Benhadji, K. ^{[8
]}

Delaloge, S. ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Invest Canc Therapeut, Houston, TX USA

[2] Sarah Cannon Res Inst, Onocl, London, England

[3] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH USA

[4] Ctr Georges Francois Leclerc, Med Oncol, Dijon, France

[5] Taiho Oncol Inc, Dept Clin Pharmacol & Pharmacometr, Princeton, NJ USA

[6] Taiho Oncol Inc, Biostat, Princeton, NJ USA

[7] Taiho Oncol Inc, Biomarkers & Compan Diagnost, Princeton, NJ USA

[8] Taiho Oncol Inc, Clin Dev, Princeton, NJ USA

[9] Inst Gustave Roussy, Intercept Med Sci Programme, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.596

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

467P

引用

页码：S754 / S755

页数：2

共 50 条

[1] A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN inactivating mutations
Rodon, J.
Funchain, P.
Laetsch, T. W.
Singer, C. F.
Arkenau, H-T.
Chawla, S. P.
Hervieu, A.
Yamamiya, I.
Liu, M.
Benhadji, K. A.
Takahashi, O.
Delaloge, S.
ANNALS OF ONCOLOGY, 2021, 32 : S616 - S617
[2] A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations
Rodon, Jordi
Funchain, Pauline
Laetsch, Theodore W.
Arkenau, Hendrik-Tobias
Hervieu, Alice
Singer, Christian F.
Murciano-Goroff, Yonina R.
Chawla, Sant P.
Anthony, Kristin
Yamamiya, Ikuo
Liu, Mei
Halim, Abdel-Baset
Benhadji, Karim A.
Takahashi, Osamu
Delaloge, Suzette
FUTURE ONCOLOGY, 2022, 18 (30) : 3377 - 3387
[3] A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Doi, Toshihiko
Takahashi, Shunji
Aoki, Daisuke
Yonemori, Kan
Hara, Hiroki
Hasegawa, Kosei
Takehara, Kazuhiro
Harano, Kenichi
Yunokawa, Mayu
Nomura, Hiroyuki
Shimoi, Tatsunori
Horie, Koji
Ogasawara, Aiko
Okame, Shinichi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (06) : 605 - 616
[4] Dose escalation of tinostamustine in patients with advanced solid tumors
Mita, Alain
Loeffler, Markus
Bui, Nam
Mehrling, Thomas
Rimmel, Bobbie J.
Natale, Ronald B.
Kummar, Shivaani
CANCER RESEARCH, 2019, 79 (13)
[5] First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours
Yunokawa, M.
Takahashi, S.
Aoki, D.
Yonemori, K.
Hara, H.
Hasegawa, K.
Takehara, K.
Harano, K.
Nomura, H.
Noguchi, E.
Horie, K.
Ogasawara, A.
Okame, S.
Doi, T.
ANNALS OF ONCOLOGY, 2019, 30
[6] A dose escalation study of weekly docetaxel in patients with advanced solid tumors
Kouroussis, C
Agelaki, S
Mavroudis, D
Souglakos, J
Kakolyris, S
Kalbakis, K
Vardakis, N
Reppa, D
Hatzidaki, D
Samonis, G
Georgoulias, V
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (06) : 488 - 492
[7] A dose escalation study of weekly docetaxel in patients with advanced solid tumors
Ch. Kouroussis
S. Agelaki
D. Mavroudis
J. Souglakos
S. Kakolyris
K. Kalbakis
N. Vardakis
D. Reppa
D. Hatzidaki
G. Samonis
V. Georgoulias
Cancer Chemotherapy and Pharmacology, 2000, 46 : 488 - 492
[8] A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors'
Kakolyris
ONCOLOGY, 2006, 71 (3-4) : 203 - 203
[9] A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors
Kakolyris, S
Kouroussis, C
Koukourakis, M
Marvroudis, D
Malas, K
Vardakis, N
Bozionelou, V
Kalbakis, K
Georgoulias, V
ONCOLOGY, 2002, 63 (03) : 213 - 218
[10] Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors
Rasco, Drew W.
Eckhardt, S. Gail
Davar, Diwakar
Lewis, Karl
Lara-Guerra, Humberto
Alters, Susan E.
Eckert, Stephen
Rowlinson, Scott W.
Wooldridge, James E.
Carvajal, Richard D.
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →